BioStock: Continued study focus for WntResearch

With the release of WntResearch’s fourth quarter 2022 financial report, two factors are in focus for the cancer therapy company. The first is the new observations made in the NeoFox study, and the second is the share issue that was carried out shortly after the turn of the year. BioStock contacted CEO Pernilla Sandwall to hear more about the past year and the company's plans for 2023.

Read the article on WntResearch's last quarter at biostock.se: 

https://www.biostock.se/en/2023/02/continued-study-focus-for-wntresearch/

This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/en/